Intrexon Corp(NYSE:XON) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $52.50M. Analysts estimated a revenue of $53.78M. Earnings per share were $-0.42. Analysts had estimated an EPS of $-0.26.
Intrexon Corp (XON) made into the market gainers list on Wednesdays trading session with the shares advancing 2.38% or 0.68 points. Due to strong positive momentum, the stock ended at $29.26, which is also near the day’s high of $29.74. The stock began the session at $28.45 and the volume stood at 24,24,081 shares. The 52-week high of the shares is $53.39 and the 52 week low is $18.5201. The company has a current market capitalization of $3,462 M and it has 11,83,25,697 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Dec 14, 2015, Randal J Kirk (CEO) purchased 124,475 shares at $29.84 per share price.Also, On Dec 4, 2015, Krish S Krishnan (Chief Operating Officer) sold 20,900 shares at $33.02 per share price.On Dec 4, 2015, Suma Krishnan (SVP–Product Development) sold 20,900 shares at $33.02 per share price, according to the Form-4 filing with the securities and exchange commission.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.